In 2020, China CDE reviewed & approved 11,582 drug registrations. The summarize the accomplishments and failures of drug approvals, CDE released a China Drug Evaluation Report of the year. Part 1 of the report gives an overview of drug approvals for all application types (incl. INDs, NDAs and ANDAs), new drug approvals for hot topics in 2020, and insights for REJECTED applications.
If you're interested can read more here:
https://pharmaboardroom.com/articles/cdes-china-drug-evaluation-report-2020-part-1/------------------------------
Raymond Ng
China Regulatory Affairs
Accestra Consulting
China Regulatory Outsourcing for Food & Drug for NMPA/CFDA registration of China Drug: NDA/IND/DMF/APIs
www.accestra.com------------------------------